Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 338

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 338
---
              | 1.25 |     |              |   (266 | ) |     |              |     (1 | ) |

Notes:

| (1) | Values in thousands of US dollars, except beta data. |

| (2) | Corresponding values continued in table below. |

| (3) | Source: S&P Capital IQ. |

Beta Calculation Information (Continued)

| Comparable Company Names                           |     | Effective 
 Tax Rate  |      |   |     | If Tax Rate = 
 “NM”, Use:    |      |   |     | Pre-Tax      
 Cost of Debt |      |   |     | After-Tax Cost of 
 Debt              |      |   |
| Amgen Inc. (NasdaqGS:AMGN)                         |     |           | 12.2 | % |     |               | 21.0 | % |     |              | 13.6 | % |     |                   | 11.9 | % |
| Pacira BioSciences, Inc. (NasdaqGS:PCRX)           |     |           | 42.4 | % |     |               | 21.0 | % |     |              | 13.6 | % |     |                   |  7.8 | % |
| CVS Health Corporation (NYSE:CVS)                  |     |           | 27.8 | % |     |               | 21.0 | % |     |              | 13.6 | % |     |                   |  9.8 | % |
| Pfizer Inc. (NYSE:PFE)                             |     |           |   NM |   |     |               | 21.0 | % |     |              | 13.6 | % |     |                   | 10.7 | % |
| Eli Lilly and Company (NYSE:LLY)                   |     |           | 12.4 | % |     |               | 21.0 | % |     |              | 13.6 | % |     |                   | 11.9 | % |
| Viatris Inc. (NasdaqGS:VTRS)                       |     |           |  0.5 | % |     |               | 21.0 | % |     |              | 13.6 | % |     |                   | 13.5 | % |
| Teva Pharmaceutical Industries Limited (NYSE:TEVA) |